| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurology | 16 | 2023 | 45 | 7.130 |
Why?
|
| Students, Medical | 13 | 2023 | 131 | 5.500 |
Why?
|
| Brain Neoplasms | 26 | 2022 | 638 | 4.940 |
Why?
|
| Glioma | 12 | 2022 | 136 | 4.150 |
Why?
|
| Internship and Residency | 10 | 2022 | 313 | 3.370 |
Why?
|
| Education, Medical | 5 | 2018 | 69 | 2.470 |
Why?
|
| Humans | 99 | 2023 | 32005 | 2.330 |
Why?
|
| Glioblastoma | 7 | 2020 | 156 | 2.180 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 608 | 1.890 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2015 | 29 | 1.870 |
Why?
|
| Fellowships and Scholarships | 3 | 2018 | 52 | 1.740 |
Why?
|
| Radial Neuropathy | 2 | 2023 | 11 | 1.690 |
Why?
|
| Meningeal Neoplasms | 4 | 2022 | 49 | 1.680 |
Why?
|
| Brain | 5 | 2021 | 951 | 1.540 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 185 | 1.510 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 367 | 1.430 |
Why?
|
| Astrocytoma | 4 | 2021 | 29 | 1.410 |
Why?
|
| Neurofibromatosis 1 | 3 | 2019 | 9 | 1.360 |
Why?
|
| Nervous System Diseases | 4 | 2018 | 39 | 1.360 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 1.330 |
Why?
|
| Curriculum | 6 | 2023 | 213 | 1.300 |
Why?
|
| Tuberous Sclerosis | 2 | 2019 | 8 | 1.220 |
Why?
|
| Immunotherapy | 3 | 2018 | 81 | 1.200 |
Why?
|
| Pituitary Neoplasms | 2 | 2017 | 17 | 1.100 |
Why?
|
| Adenoma | 2 | 2017 | 35 | 1.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2018 | 40 | 1.070 |
Why?
|
| Dacarbazine | 3 | 2016 | 29 | 1.050 |
Why?
|
| Neoplasms | 3 | 2023 | 726 | 1.050 |
Why?
|
| Female | 37 | 2023 | 19959 | 1.040 |
Why?
|
| Clinical Competence | 5 | 2018 | 333 | 0.970 |
Why?
|
| Communication | 5 | 2021 | 142 | 0.950 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 458 | 0.920 |
Why?
|
| Stroke | 3 | 2020 | 585 | 0.890 |
Why?
|
| Mentors | 2 | 2013 | 31 | 0.890 |
Why?
|
| Sulfones | 2 | 2020 | 21 | 0.890 |
Why?
|
| Clinical Clerkship | 1 | 2023 | 42 | 0.880 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2023 | 5 | 0.880 |
Why?
|
| Indans | 2 | 2020 | 31 | 0.880 |
Why?
|
| Electronic Health Records | 2 | 2015 | 162 | 0.870 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 51 | 0.870 |
Why?
|
| Deep Brain Stimulation | 2 | 2015 | 49 | 0.850 |
Why?
|
| Male | 29 | 2021 | 19165 | 0.830 |
Why?
|
| Middle Aged | 23 | 2021 | 11817 | 0.800 |
Why?
|
| Meningioma | 2 | 2022 | 57 | 0.780 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2021 | 7 | 0.780 |
Why?
|
| Buprenorphine | 1 | 2021 | 13 | 0.780 |
Why?
|
| Medical Oncology | 2 | 2021 | 86 | 0.750 |
Why?
|
| Students, Health Occupations | 1 | 2020 | 8 | 0.740 |
Why?
|
| Aged | 18 | 2023 | 10301 | 0.740 |
Why?
|
| Education, Pharmacy | 1 | 2020 | 13 | 0.740 |
Why?
|
| Telemedicine | 1 | 2022 | 102 | 0.730 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 55 | 0.730 |
Why?
|
| Neurosciences | 2 | 2019 | 11 | 0.710 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.700 |
Why?
|
| Movement Disorders | 2 | 2010 | 26 | 0.700 |
Why?
|
| Ketone Bodies | 1 | 2019 | 8 | 0.700 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.690 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.690 |
Why?
|
| Physicians | 2 | 2019 | 158 | 0.680 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.680 |
Why?
|
| Faculty, Medical | 2 | 2017 | 78 | 0.680 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 83 | 0.680 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 765 | 0.660 |
Why?
|
| Learning | 2 | 2019 | 79 | 0.650 |
Why?
|
| Adult | 17 | 2022 | 9345 | 0.620 |
Why?
|
| Retrospective Studies | 13 | 2022 | 3509 | 0.620 |
Why?
|
| Neurilemmoma | 1 | 2017 | 16 | 0.610 |
Why?
|
| Wrist | 3 | 2023 | 48 | 0.590 |
Why?
|
| Skin | 1 | 2019 | 211 | 0.590 |
Why?
|
| Ultrasonography | 1 | 2020 | 379 | 0.580 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 412 | 0.580 |
Why?
|
| Weight Gain | 2 | 2015 | 117 | 0.570 |
Why?
|
| Truth Disclosure | 1 | 2016 | 13 | 0.570 |
Why?
|
| Neuromuscular Agents | 1 | 2017 | 29 | 0.560 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 301 | 0.560 |
Why?
|
| Parkinson Disease | 2 | 2015 | 87 | 0.560 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2016 | 2 | 0.540 |
Why?
|
| Dietary Supplements | 2 | 2015 | 185 | 0.540 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 5 | 0.540 |
Why?
|
| Subthalamic Nucleus | 1 | 2015 | 13 | 0.530 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 28 | 0.520 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 13 | 0.520 |
Why?
|
| Goals | 1 | 2015 | 36 | 0.520 |
Why?
|
| Prospective Studies | 5 | 2023 | 2282 | 0.510 |
Why?
|
| Germinoma | 1 | 2015 | 2 | 0.510 |
Why?
|
| Tremor | 1 | 2015 | 11 | 0.500 |
Why?
|
| Prolactinoma | 1 | 2015 | 1 | 0.500 |
Why?
|
| Brain Stem | 1 | 2015 | 20 | 0.500 |
Why?
|
| Lymphoma | 1 | 2015 | 35 | 0.490 |
Why?
|
| Hemianopsia | 1 | 2014 | 6 | 0.470 |
Why?
|
| Glucose | 1 | 2015 | 174 | 0.470 |
Why?
|
| Case-Control Studies | 5 | 2017 | 898 | 0.460 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.460 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2013 | 8 | 0.460 |
Why?
|
| Pseudolymphoma | 1 | 2013 | 4 | 0.450 |
Why?
|
| Hyperglycemia | 1 | 2014 | 84 | 0.450 |
Why?
|
| Glucocorticoids | 1 | 2015 | 146 | 0.450 |
Why?
|
| Teaching | 2 | 2014 | 62 | 0.440 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.440 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 78 | 0.440 |
Why?
|
| Semen | 1 | 2013 | 10 | 0.430 |
Why?
|
| Patient Readmission | 1 | 2014 | 126 | 0.430 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.430 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 6 | 0.430 |
Why?
|
| Sperm Motility | 1 | 2013 | 8 | 0.430 |
Why?
|
| Prognosis | 8 | 2023 | 1497 | 0.430 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 8 | 0.420 |
Why?
|
| Paresis | 1 | 2012 | 13 | 0.420 |
Why?
|
| Transients and Migrants | 1 | 2016 | 290 | 0.420 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.420 |
Why?
|
| Functional Laterality | 1 | 2012 | 56 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2022 | 3306 | 0.420 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 28 | 0.420 |
Why?
|
| Horner Syndrome | 1 | 2012 | 1 | 0.410 |
Why?
|
| Spider Venoms | 1 | 2012 | 3 | 0.410 |
Why?
|
| Educational Measurement | 2 | 2010 | 123 | 0.410 |
Why?
|
| Schools, Medical | 3 | 2019 | 43 | 0.410 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 2265 | 0.410 |
Why?
|
| Education, Medical, Undergraduate | 4 | 2021 | 86 | 0.400 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 49 | 0.400 |
Why?
|
| Spinal Diseases | 1 | 2012 | 16 | 0.400 |
Why?
|
| Arteriovenous Fistula | 1 | 2012 | 18 | 0.400 |
Why?
|
| Steroids | 1 | 2012 | 38 | 0.400 |
Why?
|
| Comprehensive Health Care | 1 | 2011 | 5 | 0.380 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 12 | 0.370 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 99 | 0.370 |
Why?
|
| Community Health Centers | 1 | 2011 | 16 | 0.370 |
Why?
|
| Esophagus | 1 | 2010 | 22 | 0.360 |
Why?
|
| Hematoma | 1 | 2010 | 27 | 0.360 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 83 | 0.360 |
Why?
|
| Pseudobulbar Palsy | 1 | 2010 | 5 | 0.360 |
Why?
|
| Mood Disorders | 1 | 2010 | 21 | 0.360 |
Why?
|
| Quality of Life | 3 | 2019 | 946 | 0.360 |
Why?
|
| Pilot Projects | 3 | 2020 | 545 | 0.350 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1531 | 0.340 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.340 |
Why?
|
| Electrodiagnosis | 2 | 2020 | 42 | 0.320 |
Why?
|
| Anxiety | 1 | 2010 | 191 | 0.310 |
Why?
|
| Radiotherapy | 2 | 2019 | 82 | 0.310 |
Why?
|
| Survival Rate | 5 | 2018 | 877 | 0.310 |
Why?
|
| Neural Conduction | 2 | 2020 | 91 | 0.310 |
Why?
|
| Chest Pain | 1 | 2010 | 208 | 0.300 |
Why?
|
| Patient Care Team | 2 | 2020 | 129 | 0.280 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 560 | 0.280 |
Why?
|
| Cohort Studies | 3 | 2020 | 1817 | 0.270 |
Why?
|
| Radiosurgery | 2 | 2022 | 356 | 0.270 |
Why?
|
| Weight Loss | 1 | 2010 | 480 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 1328 | 0.260 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 517 | 0.260 |
Why?
|
| Neurologic Examination | 2 | 2017 | 28 | 0.250 |
Why?
|
| Electromyography | 2 | 2017 | 59 | 0.240 |
Why?
|
| Educational Status | 2 | 2022 | 179 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 3990 | 0.230 |
Why?
|
| Genomics | 3 | 2021 | 85 | 0.230 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 726 | 0.230 |
Why?
|
| Consensus | 2 | 2021 | 85 | 0.230 |
Why?
|
| Animals | 6 | 2022 | 7541 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 115 | 0.220 |
Why?
|
| Problem-Based Learning | 1 | 2023 | 28 | 0.220 |
Why?
|
| Paclitaxel | 2 | 2022 | 67 | 0.220 |
Why?
|
| Quality of Health Care | 2 | 2017 | 147 | 0.220 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 16 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 15 | 0.210 |
Why?
|
| Hypesthesia | 1 | 2022 | 9 | 0.210 |
Why?
|
| Mice | 4 | 2022 | 2484 | 0.210 |
Why?
|
| Elbow | 1 | 2022 | 26 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 99 | 0.200 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 2 | 0.200 |
Why?
|
| Prevalence | 2 | 2018 | 981 | 0.200 |
Why?
|
| Ketosis | 1 | 2021 | 1 | 0.200 |
Why?
|
| Fasting | 1 | 2021 | 95 | 0.190 |
Why?
|
| Health Occupations | 1 | 2020 | 2 | 0.190 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 6 | 0.190 |
Why?
|
| Societies | 1 | 2020 | 6 | 0.180 |
Why?
|
| Patient Simulation | 1 | 2020 | 32 | 0.180 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 48 | 0.180 |
Why?
|
| Disease Progression | 3 | 2018 | 594 | 0.180 |
Why?
|
| Feasibility Studies | 1 | 2021 | 293 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 160 | 0.180 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.180 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.180 |
Why?
|
| Albumins | 1 | 2020 | 45 | 0.180 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.170 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.170 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2019 | 3 | 0.170 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2019 | 4 | 0.170 |
Why?
|
| Leg | 1 | 2020 | 65 | 0.170 |
Why?
|
| Mice, Nude | 1 | 2020 | 291 | 0.170 |
Why?
|
| Cell Movement | 1 | 2020 | 169 | 0.170 |
Why?
|
| Meninges | 1 | 2019 | 1 | 0.170 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2019 | 6 | 0.170 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 232 | 0.160 |
Why?
|
| Serial Publications | 1 | 2018 | 3 | 0.160 |
Why?
|
| Peer Group | 1 | 2019 | 44 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2019 | 49 | 0.160 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.160 |
Why?
|
| Biopsy | 2 | 2017 | 259 | 0.160 |
Why?
|
| Gangrene | 1 | 2018 | 4 | 0.160 |
Why?
|
| Paraplegia | 1 | 2018 | 7 | 0.160 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2018 | 5 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2019 | 181 | 0.160 |
Why?
|
| RNA Interference | 1 | 2018 | 76 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 447 | 0.150 |
Why?
|
| Foot | 1 | 2018 | 39 | 0.150 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2017 | 1 | 0.150 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 114 | 0.150 |
Why?
|
| Societies, Scientific | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2020 | 604 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2017 | 49 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2018 | 41 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 25 | 0.150 |
Why?
|
| Time Management | 1 | 2017 | 9 | 0.150 |
Why?
|
| Headache | 1 | 2018 | 75 | 0.150 |
Why?
|
| Young Adult | 4 | 2018 | 2636 | 0.150 |
Why?
|
| Focus Groups | 1 | 2018 | 113 | 0.150 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 143 | 0.150 |
Why?
|
| Hospice Care | 1 | 2017 | 13 | 0.150 |
Why?
|
| Terminal Care | 1 | 2017 | 24 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 181 | 0.140 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 15 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2017 | 70 | 0.140 |
Why?
|
| Muscle Weakness | 1 | 2017 | 37 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2018 | 167 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2018 | 121 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2017 | 119 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 127 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2020 | 682 | 0.140 |
Why?
|
| Head | 1 | 2017 | 51 | 0.140 |
Why?
|
| Epilepsy | 1 | 2017 | 82 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 78 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.140 |
Why?
|
| Lumbosacral Plexus | 1 | 2016 | 5 | 0.140 |
Why?
|
| Neurofibromatosis 2 | 1 | 2016 | 5 | 0.140 |
Why?
|
| Lomustine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Procarbazine | 1 | 2016 | 5 | 0.130 |
Why?
|
| Carmustine | 1 | 2016 | 8 | 0.130 |
Why?
|
| Vincristine | 1 | 2016 | 17 | 0.130 |
Why?
|
| Bone Density | 1 | 2017 | 205 | 0.130 |
Why?
|
| Dermatomyositis | 1 | 2016 | 19 | 0.130 |
Why?
|
| beta Catenin | 1 | 2016 | 37 | 0.130 |
Why?
|
| Publications | 1 | 2015 | 9 | 0.130 |
Why?
|
| Time Factors | 3 | 2021 | 2149 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 19 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 94 | 0.130 |
Why?
|
| Methylprednisolone | 1 | 2015 | 12 | 0.130 |
Why?
|
| Prolactin | 1 | 2015 | 10 | 0.130 |
Why?
|
| Retreatment | 1 | 2015 | 41 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 447 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 407 | 0.120 |
Why?
|
| Intracranial Hemorrhages | 1 | 2014 | 33 | 0.120 |
Why?
|
| Physician's Role | 1 | 2014 | 40 | 0.120 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 23 | 0.120 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 371 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2015 | 147 | 0.120 |
Why?
|
| Documentation | 1 | 2014 | 46 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 632 | 0.120 |
Why?
|
| Biological Products | 1 | 2015 | 77 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 54 | 0.110 |
Why?
|
| Sex Factors | 1 | 2015 | 663 | 0.110 |
Why?
|
| Risk Factors | 1 | 2022 | 3876 | 0.110 |
Why?
|
| Adolescent | 4 | 2018 | 3539 | 0.110 |
Why?
|
| Pipecolic Acids | 1 | 2012 | 6 | 0.110 |
Why?
|
| Hirudins | 1 | 2012 | 19 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2012 | 13 | 0.110 |
Why?
|
| Vena Cava Filters | 1 | 2012 | 13 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 30 | 0.110 |
Why?
|
| Electroencephalography | 3 | 2022 | 73 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 34 | 0.110 |
Why?
|
| Warfarin | 1 | 2012 | 29 | 0.110 |
Why?
|
| Diet | 1 | 2015 | 391 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2015 | 494 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2014 | 146 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 49 | 0.100 |
Why?
|
| Black Widow Spider | 1 | 2012 | 1 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 247 | 0.100 |
Why?
|
| Paraparesis | 1 | 2012 | 3 | 0.100 |
Why?
|
| Seafood | 1 | 2012 | 11 | 0.100 |
Why?
|
| Food Hypersensitivity | 1 | 2012 | 8 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2012 | 100 | 0.100 |
Why?
|
| Dura Mater | 1 | 2012 | 14 | 0.100 |
Why?
|
| Anaphylaxis | 1 | 2012 | 12 | 0.100 |
Why?
|
| Prednisone | 1 | 2012 | 61 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2012 | 122 | 0.100 |
Why?
|
| Angiography | 1 | 2012 | 80 | 0.100 |
Why?
|
| North Carolina | 1 | 2016 | 1514 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 88 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 881 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 471 | 0.090 |
Why?
|
| Alendronate | 1 | 2010 | 11 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 23 | 0.090 |
Why?
|
| Emaciation | 1 | 2010 | 4 | 0.090 |
Why?
|
| Licensure, Medical | 1 | 2010 | 4 | 0.090 |
Why?
|
| Essential Tremor | 1 | 2010 | 12 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 74 | 0.090 |
Why?
|
| Acute Disease | 1 | 2010 | 253 | 0.090 |
Why?
|
| Receptor, erbB-2 | 2 | 2020 | 65 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2010 | 75 | 0.090 |
Why?
|
| Health Surveys | 1 | 2010 | 196 | 0.080 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2009 | 8 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 406 | 0.080 |
Why?
|
| Spinal Nerves | 1 | 2009 | 65 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 166 | 0.080 |
Why?
|
| Comorbidity | 1 | 2010 | 566 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2012 | 780 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 876 | 0.070 |
Why?
|
| Decision Making | 1 | 2009 | 195 | 0.070 |
Why?
|
| Disease Management | 2 | 2018 | 126 | 0.070 |
Why?
|
| Sensation | 1 | 2006 | 55 | 0.070 |
Why?
|
| Attention | 1 | 2006 | 83 | 0.070 |
Why?
|
| Germinal Center | 1 | 2023 | 5 | 0.050 |
Why?
|
| Immersion | 1 | 2022 | 3 | 0.050 |
Why?
|
| Competency-Based Education | 1 | 2022 | 6 | 0.050 |
Why?
|
| Gelatin | 1 | 2022 | 29 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 43 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 52 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 82 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 121 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 94 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 225 | 0.050 |
Why?
|
| Hyperalgesia | 1 | 2022 | 78 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 64 | 0.050 |
Why?
|
| Intention | 1 | 2021 | 28 | 0.050 |
Why?
|
| Attitude | 1 | 2021 | 40 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 99 | 0.050 |
Why?
|
| Anilides | 1 | 2020 | 10 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 19 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2020 | 30 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 25 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2020 | 66 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 126 | 0.050 |
Why?
|
| Minority Groups | 1 | 2021 | 78 | 0.050 |
Why?
|
| Pyridines | 1 | 2020 | 76 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2020 | 67 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 217 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 85 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 65 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 104 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 220 | 0.040 |
Why?
|
| Astrocytes | 1 | 2019 | 58 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 415 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 510 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 7 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 767 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 57 | 0.040 |
Why?
|
| Models, Educational | 1 | 2019 | 20 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 130 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 62 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 108 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 105 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 103 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 74 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 28 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 276 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 476 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 261 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 96 | 0.040 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 240 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2018 | 51 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2017 | 25 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 256 | 0.040 |
Why?
|
| Craniotomy | 1 | 2017 | 46 | 0.040 |
Why?
|
| Neutrophils | 1 | 2017 | 106 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 101 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 53 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2022 | 656 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 158 | 0.030 |
Why?
|
| Child | 1 | 2022 | 2438 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 313 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1188 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 835 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2014 | 37 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2014 | 120 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1426 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2009 | 28 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2006 | 17 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2006 | 126 | 0.020 |
Why?
|
| Reaction Time | 1 | 2006 | 117 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2006 | 158 | 0.020 |
Why?
|